Dong-A ST Co., Ltd. (KRX:170900)
South Korea
· Delayed Price · Currency is KRW 44,800
-550 (-1.21%)
Apr 29, 2026, 3:30 PM KST
Dong-A ST Revenue
In the year 2025, Dong-A ST had annual revenue of 808.78B KRW with 15.89% growth. Dong-A ST had revenue of 216.77B in the quarter ending December 31, 2025, with 21.36% growth.
Revenue
808.78B
Revenue Growth
+15.89%
P/S Ratio
0.54
Revenue / Employee
481.70M
Employees
1,679
Market Cap
435.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 808.78B | 110.91B | 15.89% |
| Dec 31, 2024 | 697.87B | 33.89B | 5.10% |
| Dec 31, 2023 | 663.98B | 28.59B | 4.50% |
| Dec 31, 2022 | 635.39B | 42.16B | 7.11% |
| Dec 31, 2021 | 593.23B | 6.50B | 1.11% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| FutureChem Co.,Ltd | 18.67B |
| EuBiologics | 96.04B |
| Humedix | 110.99B |
| Yungjin Pharm. | 158.79B |
| Shinpoong Pharmaceutical Co.,Ltd | 234.68B |
| Huons | 620.77B |
| Dong-A Socio Holdings | 1,429.77B |
| JW Holdings | 969.57B |
Dong-A ST News
- 1 year ago - Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA - Financial Post
- 1 year ago - US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Financial Post
- 1 year ago - US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Benzinga